VIP (5mg)

Vasoactive Intestinal Peptide (VIP), also known as vasoactive intestinal polypeptide or PHM27, is a short peptide hormone that is synthesized in the gastrointestinal tract, pancreas, and central nervous system of most vertebrate species, including humans. VIP elicits its physiological effects by binding to class II G protein-coupled receptors.

 VIP is known to

•  increase the breakdown of glycogen in liver and muscle,

• lower blood pressure,

•  relax smooth muscle throughout the GI tract,

• stimulate contraction of cardiac muscle (by boosting both heart rate and strength of contractions),

• stimulate the secretion of water in various areas of the GI tract,

• affect vaginal lubrication,

• regulate prolactin release

• protect cartilage,

• affect autonomic nerve function, and

•  protect neurons against ischemia and oxidative stress,

• help to synchronize the central nervous system (specifically neurons in the suprachiasmatic nucleus) with light cues for regulating circadian rhythm.

VIP has garnered substantial interest for numerous compelling reasons. Extensive scientific literature exists on this specific peptide, rendering it impractical to comprehensively cover all facets of VIP research. Presented below is a succinct overview of key highlights, notably encapsulating the paramount aspect of VIP research: the discovery of its capacity to mitigate inflammation and fibrosis across various organs.

DISCLAIMER: FOR EXPERIMENTAL USE ONLY, NOT FOR PERSONAL USE